Suggested remit: To appraise the clinical and cost effectiveness of triheptanoin within its marketing authorisation for treating long-chain fatty acid oxidation disorders.
 
Status Awaiting development
Technology type Medicine
Decision Awaiting decision
Process STA Standard
ID number 3891

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
13 December 2024 Awaiting development. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early June 2025 when we will write to you about how you can get involved.
10 December 2024 (10:00) Scoping workshop
21 October 2024 - 18 November 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3891
21 October 2024 In progress. Scoping commencing
22 April 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early February 2025. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
27 November 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
27 November 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual